A groundbreaking world-first trial is set to investigate whether the immune system plays a role in repeated failed IVF attempts, potentially offering new answers to patients who have endured multiple unsuccessful pregnancies. The trial, hailed as a major breakthrough, focuses on natural killer cells, a critical component of the immune system that helps attach the embryo to the womb. However, an excess of these cells can hinder implantation.
Patient Story Highlights Emotional and Financial Toll
Ria Miocevich, a mother who struggled to conceive, shared her harrowing journey with 7NEWS.com.au. She underwent seven egg collections, 11 embryo transfers, and experienced several miscarriages and first-trimester losses. “It was heartbreaking and gut-wrenching at times,” Miocevich said. Each IVF cycle cost at least $15,000, but her daughter Melena made it all worthwhile. “Just pure joy. So much happiness. It’s life-changing,” she added. It took Miocevich and her partner four gruelling years to fall pregnant, without knowing the underlying cause.
Trial Details and Recruitment
Led by fertility specialist Dr Rose McDonnell at Genea, the national trial aims to crack the embryo code by examining natural killer cell activity. “Ten to 15 per cent of women are affected by recurrent implantation failure or recurrent miscarriage,” Dr McDonnell explained. A simple blood test will determine eligibility for the trial, which is recruiting up to 1600 IVF patients across Australia—the largest study of its kind worldwide. The trial has already commenced in Western Australia, with Sydney set to follow soon.
Potential Benefits for Patients
The trial could transform treatment by identifying immune abnormalities before embryo transfer. “Patients like Ria can benefit from knowing ahead of time before the embryo is implanted if the natural cell activity or number is abnormal,” Dr McDonnell said. “And this will give them an opportunity to change the immune environment to facilitate implantation.” This approach may reduce the emotional and financial burden of repeated IVF cycles, offering new hope to those struggling with infertility.
